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ABSTRACT
Codeine phosphate is a mild to moderate analgesic and has a weak cough suppressant activity that is
available to purchase as an over the counter (OTC) painkiller in Ireland as a compound product. In
recent years, countries such as Australia have introduced laws that prohibit the sale of the drug without
a valid prescription. The primary aims of the study were to determine knowledge among the public of
codeine-containing medications and their usage levels. The survey also investigated whether current
regulations and recommendations are being followed in Ireland. The survey was distributed to 543 Irish
adults using an online platform in February 2020. Only 47.2% (n=256) of those surveyed were able to
correctly identify a codeine-containing medicine from a list provided.
Analysis of the results obtained from the study revealed that only 8.6% of the surveyed population were
unaware of the potentially addictive nature of the drug. Consumers were more likely to be questioned
and sold an over the counter (OTC) codeine-containing medicine under the supervision of a member of
pharmacy staff rather than the pharmacist (73%) which is not compliant with Irish Law. This may pose
a potential danger to patient safety. An examination of the population’s opinion on whether the drug
should remain an OTC medicine or introduce changes in regulation that would make the drug a
prescription-only item showed that 47% of those asked believed that the medicine should remain OTC,
while 53% would be of the opposing opinion.

INTRODUCTION
Codeine phosphate is a mild to moderate analgesic and has a weak cough suppressant activity that is
often sold in conjunction with other over-the-counter analgesics. The Pharmaceutical Society of Ireland
(PSI) currently recognises codeine as a schedule 5 controlled drug; as such it may be purchased in a
pharmacy without a prescription under the supervision of a pharmacist (PSI, 2019). Compound codeine
products can currently be purchased over the counter (OTC) in 12 of the 27 EU states and also within
the United Kingdom. A compound codeine product contains the drug codeine, as codeine phosphate, as
an active pharmaceutical agent but may also contain one or more other active ingredients such as
paracetamol or ibuprofen.
Unlike pain medications such as paracetamol which block the release of prostaglandins to reduce pain
and inflammation (Graham, 2005), 5-10% of codeine phosphate is converted to morphine when
consumed. The morphine binds to mu-opioid receptors in the brain preventing the recognition of pain
signals (Bhandari, 2011) giving the ‘high’ or sedative qualities sometimes associated with codeine
consumption however, equally this is the reason the drug is subject to being abused.
Codeine has been demonstrated to be a highly abused substance in countries such as the United States
contributing to the so-called ‘opioid crisis’ (Kahan, 2011). Abuse of the drug has resulted in some
countries such as Australia taking legal measures to ensure that the drug cannot be misused due to ease

of access (TGA, 2020). From February 2018, medicines that contain codeine can no longer be purchased
over the counter in pharmacies in Australia and a prescription is necessary.
The purpose of the current research was to gain an insight of the knowledge individuals have on
codeine-containing medicines, where individuals source the medication and the procedure involved in
sourcing a codeine product. It is hoped that this research will begin further research into codeine
medicines in Ireland and the associated regulations.

MATERIALS & METHODS:
Survey Design
People of varying ages and who reside in the Republic of Ireland for at least 10 months of the year were
surveyed using a survey entitled “A snapshot investigation into the availability and access to codeinecontaining medications amongst the Irish Population.” An anonymous survey comprising 19 questions
was created using Google Forms where applicable, it was optional to choose multiple answers or skip
the entire question. Questions were included to gather relevant information such as participant
demographics, usage and acquisition of codeine-containing medications and knowledge of codeine
products. Opinions on the supply of codeine were also welcomed.
Distribution of the survey
The main method used to distribute the survey was online via social media platforms, namely Facebook,
WhatsApp and Instagram. It was also circulated via email among the UCC student body using the
service surveys@umail.ucc.ie. WhatsApp and Facebook were mainly used to reach the older population
(>51 years). This was important to reduce bias and the likelihood of an invalid response. The survey
was open for responses from the 18th February 2020 until the 9th March 2020..
Inclusion and exclusion criteria
For a response to be included in the data, the respondent had to be able to identify any codeinecontaining product in Question 16 of the survey. If the respondent selected a non-codeine-containing
medication, they were excluded from the data analysis. If a respondent identified a non-codeinecontaining product as a codeine-containing product it was determined that they may not have a
comprehensive understanding of the drug.
Data analysis
Data analysis was conducted us Microsoft EXCEL which allowed the responses to be organized based
on age, gender and uses of codeine. Chi square testing was used to test the statistical significance of any
novel findings, using the formula:

RESULTS
The survey yielded a total of 543 responses. These responses yielded 256 responses from individuals
who could correctly identify codeine-containing products from a provided list, 63% of whom were aged
18-28y; 10% were aged 29-39y; 9% were aged 40-50y; 18% were 50y or older. There were two
inclusion criteria which had to be met for the individual’s response to be considered for data analysis 1) the respondent had to be able to identify at least one codeine containing drug from the list provided,
and 2) the respondent did not incorrectly identify a non-codeine-containing product as a codeinecontaining product. These criteria were put in place to ensure that respondents had a suitable knowledge
of codeine containing products, which may influence their responses. The responses of these individuals
formed the basis of the results below. Figure 1 shows the means of procurement of codeine by age and
Figure 2 outlines the approach used by age of those who entered a pharmacy without a prescription.

Figure 1: Influence of age on the means of procurement of codeine containing medications.

Figure 2: Analysis of the influence of age on the purchasing protocol for individuals whose primary
means of sourcing codeine is from a pharmacy without a prescription.

Chi square statistical analysis of the apparent finding that men are twice as likely not to be asked
questions prior to purchasing Codeine-containing medications compared with women [Figure 3], found
that at a 0.1 confidence interval that the result was not significant: with a p-value of 0.1522. This
suggests that the finding may be an artifact of the disparity between the number of male and female
participants.

Figure 3: Analysis of the influence of gender on the purchasing protocol of codeine containing products.

Figure 4 shows the results of investigating the propensity to lie in order to acquire codeine, sorted by
age-group. Figure 5 shows the survey population’s opinion on whether codeine acquisition should need
a prescription, by age-group.

Figure 4: Analysis of the influence of age on an individuals’ willingness to lie to a healthcare professional
in order to obtain codeine. Each bar represents the percentage of individuals in that age cohort who admitted to
lying to obtain a codeine counting product.

Figure 5: Analysis of 256 Irish individuals’ opinions as to whether or not codeine should be prescription
only, by age group.

Figure 6: Justification of 121 Irish survey respondents who believe codeine should remain an over-thecounter drug.

Figure 6 is concerned with the respondent’s (n=121) reasons for retaining codeine containing
medications as over the counter products. The most common reason for this was the cost associated
with visiting a doctor to obtain a prescription (34%), followed by the belief current regulation of codeine
was sufficient (20%). Other reasons given were: individuals should know to use codeine containing
medications responsibly, requiring a prescription to obtain codeine containing medications would cause
an added strain on the healthcare system and some individuals believed it should be freely available
after answering a series of questions in relation to the purchase of the medication.

Figure 7 demonstrates the respondent’s (n=135) reasons for codeine containing medications being
available on prescription only. Under the category “Other” reasons supplied were that the drug is abused
and misused and that supervision of the drug is required.

Figure 7: Justifications of 135 Irish respondents who believe that codeine should be available by
prescription only.

DISCUSSION
Codeine phosphate is a mild to moderate analgesic available to purchase over the counter (OTC) in
Ireland and is often used to treat more serious types of pain that cannot be suppressed using other OTC
medications such as paracetamol or ibuprofen. Codeine has been the most consumed opiate in the world
in terms of countries in which it is consumed (International Narcotics Board, 2012).
Under Irish law, codeine is classified as schedule 5 under the Controlled Drug Regulations meaning
that it is available to patients OTC in pharmacies under the supervision of a pharmacist who should
make the patient aware of the side effects, especially of the sedating nature of the drug and emphasize
the addictive potential of the drug (PSI, 2012).
Analysis of the results obtained from the study revealed that 91.4% were aware of the potentially
addictive nature of the drug. This finding suggests that this common side-effect is well-known within
the population who can correctly identify a codeine-containing medicine. Based on these data, the
addictive nature of the drug appears to be well known.
The inability of individuals to correctly identify codeine-containing medicines was used as an exclusion
parameter for the rest of the questions, for accuracy. Current legislation in Ireland (Pharmacy Act,
2007; Regulation of Retail Pharmacy Businesses Regulations, 2008) for the supply of codeine states
that any form of advertising of codeine is strictly prohibited and it cannot be placed in the self-selection
area of a pharmacy. The inability to self-select a codeine-containing product may explain why 52.8%
of individuals incorrectly identified codeine-containing medicines.
Results illustrated in Figure 2 show that in all age brackets, consumers were more likely to be questioned
and sold an OTC codeine-containing medicine under the supervision of a member of pharmacy staff
rather than the pharmacist (73%). Over 80% of all patients aged between 40-50 were asked questions
by pharmacy staff rather than the pharmacist which is not compliant with Irish Law (Regulation of

Retail Pharmacy Businesses Regulations, 2008). More concerning, 28.5% of consumers aged 51+ were
not asked any of the necessary questions by any member of staff in the purchasing process. These
regulatory questions include who the medication is for, the type of pain experienced, the duration of
symptoms and if they are on any other medication; the purpose of asking these questions is to assess
whether the individual is suitable for codeine treatment.
Of all the population, it is this age branch who are more likely to be suffering from an underlying health
condition or taking other prescription medications which may interact with the drug and produce sideeffects. For example, antidiarrhoeal drugs such as loperamide & kaolin when taken with codeine can
result in severe constipation. Carrington Reid et al. (2015) found that chronic pain in later life is a
worldwide problem and there are many causative agents of chronic pain such as cancer, musculoskeletal
disorders such as arthritis or peripheral neuropathies.
In additional investigations into the impact of age on purchasing procedure it showed there was a clear
positive correlation between age and individuals not being asked questions was seen (R = 0.92). This
may be due to the assumption that older adults (51+) are less likely to abuse substances such as codeine;
however, the fact that individuals, particularly of this age group, are less likely to be asked questions
regarding the purpose of purchase is worrying. Whilst there is limited research into the effect codeine
is having in Ireland, a comprehensive 13-year study in Australia identified the prevalence of accidental
codeine overdoses. The data highlighted that the majority of accidental deaths were in individuals over
the age of 50 (30%) (Cairns et al., 2019).
This study found that younger respondents were found to be more likely to obtain codeine from family
and friends, with 29–39-year-olds being more than twice as likely to obtain codeine from friends than
any other group (17%). The 18–28-year-olds were also seen to obtain codeine from friends and family;
however, this was less common (7%). It is postulated that the increased number of younger people
sharing codeine medications may be associated with the lower prescription rate of codeine in individuals
<39yrs (23%), compared with individuals of 39yrs or older, who were more likely to receive the drug
on prescription (55%). A systematic review by (Beyene et al, 2014) on the subject of sharing
prescription medications demonstrated a similar result Regardless of the reasoning, the sharing of
potentially addictive drugs is suboptimal. It is also unlikely when supplying these medications that
family members/friends who supply the medication would advise of potential side-effects or the
addictive nature of codeine; and as such, may be unwittingly fuelling addiction as suggested by
Kennedy-Hendrick et al. (2016).
In an investigation of the relationship between gender and the purchasing process, illustrated in Figure
3, males were twice as likely to receive a codeine-containing medicine without any form of a
consultation process. Chi-square statistics tested determined that at a 10% confidence interval, the result
was statistically insignificant suggesting that this finding may be the result of differences in sample size
between men and women. However, as the p-value was 0.15, further study using a larger sample
population with a more even gender distribution could be used to investigate again for inequalities when
it comes to the impact of gender on the procurement of controlled substances.
Of the 15% of survey respondents willing to lie to obtain codeine (Figure 4), most of the individuals
justified their lying by stating it was easier to receive the medication this way (68%) whilst most others
said they were aware of the side effects and did not require advice (31%). The rate of lying was
particularly high in 29-39-year-old age group (22%), and it is noteworthy that Cairns et al. (2019)
recognised that 30-39 year-olds made up the second greatest proportion of unintentional codeine
overdose (28.8%).
Subsequently, the sub-population of individuals who did not use their codeine for its intended medical
purpose (herein referred to as codeine misuse) was examined. Of the 59 respondents who obtained
codeine from a pharmacy with a prescription, all used the product for its intended medicinal purpose,
with 53 of these individuals using the codeine medication for pain relief and the remainder using it for

cough relief. Similar findings were seen among individuals who obtained codeine from family and
friends.
However, when the 118 individuals who obtained codeine from a pharmacy without a prescription was
examined, 98 individuals consumed codeine for pain relief whilst 13 used the drug for cough
suppression. The remaining 9 individuals who obtained codeine from a pharmacy without a prescription
abused the drug for recreational use, euphoria, or relaxation purposes. These figures suggest that
individuals who obtain codeine for non-medicinal purposes are most likely to obtain the drug from a
pharmacy without a prescription. Of the 9 individuals who admitted to abusing codeine, four were 18–
28-year-old full-time third level students who used the drug for recreational purposes. Two individuals
were aged 40-50, and one aged 61+. Two of these participants both aged 29-39 admitted to being reliant
on codeine and agreed that codeine was widely available and easy to obtain. Perhaps the most alarming
piece of data obtained from the subset of codeine misusers, is that all the individuals described their
purchasing procedure as being asked questions by pharmacy staff rather than being referred to a
pharmacist. This finding highlights the need for stronger enforcement of regulation around codeine.
The examination of the populations' opinion on whether the drug should remain an OTC medicine or
introduce changes in regulation which would make the drug a prescription-only item the population is
closely split and those whose opinion is that it should remain OTC are differentiated by age-group in
Figure 5. The main validation for the belief that codeine should remain an OTC product (Figure 6)
included the cost associated with obtaining and renewing prescriptions (41%), followed by the idea that
current procedures and guidelines are adequate (24%) and that other pain-relieving OTC drugs are not
as effective (19%). Those who believe that regulations surrounding the drug need to be adjusted gave
the following reasons: the addictive nature of the drug (62%), maintaining patient safety (14%), and to
prevent abuse of the drug (8%)
All age categories, except one, suggested that the drug should only be available on prescription.
Notably, 72% of respondents aged 29-39y believe the drug should be available to purchase without a
prescription. Reasons for this were found to largely be associated with the added cost and wait time that
would be associated with obtaining the drug. It was also established that this age group is also the most
likely to obtain codeine from a family member or friend (8%) and represents the age group most likely
to lie to obtain codeine (22%). The suggestion by respondents that the cost of the drug would increase
with a change in regulations is a valid one. These additional charges would come from GP consultation
fees and the added pharmacy dispensing fee. The average GP visit fee in Ireland is €55-60 (Weston,
2019) and the average pharmacy dispensing fee can vary greatly dependent upon the items being
dispensed. This increase in cost would primarily affect private healthcare patients who are not enrolled
in any drug-related schemes such as the medical card (GMS) or drugs payment scheme (DPS). It was
also found that there is concern amongst the public that making codeine available on prescription only
would encourage those that are dependent on the medication to turn to illegal substance abuse due to
the additional costs associated with obtaining the drug (Shying., 2018).
A recent study published in 2019 showed that since the introduction of stricter measures on the sale of
the drug, which was enforced by the PSI through inspection, that there was a 33% decrease in the
number of codeine related overdoses in Ireland (Kennedy et al., 2019).
To conclude, the data obtained from this survey suggest that common side-effects of codeine are widely
known amongst the population. Clearly the surveyed population are mostly concerned with the
addictive nature of the drug and the impact it can have on the well-being of others as demonstrated in
figure 7. Considering the addictive nature of the drug, the low percentage (47%) of the population who
can differentiate between codeine-containing and non-codeine containing medications was concerning.
As most of the population surveyed purchased codeine over the counter, there is a need for additional
education of the population on the safe use and the dangers of codeine-containing products. Our findings
suggest a need for mandatory training to be introduced for all pharmacy staff on the protocol regarding
the sale of the drug, if only to act as a reminder of the legislation.

ACKNOWLEDGEMENTS
We would like to thank Dr Brigid Lucey, CIT for the guidance offered in constructing this paper, and
Mr David O’Riordan, UCC and Luigi Barlassina, Pharmacist for the assistance with constructing the
questionnaire. We would also like to show our gratitude to Dr Michelle Foley, WIT for providing
feedback on the direction of the paper and Dr Sean Lacey, CIT for aiding us in determining statistical
significance.

Corresponding author: Katie O’ Brien (katieobrien1999@gmail.com)

REFERENCES
Graham GG, Scott KF, 2005. Mechanism of action of
https://www.ncbi.nlm.nih.gov/pubmed/15662292 [Accessed 2, Apr 2020]

paracetamol.

Available

at:

Bhandari, M., Bhandari, A. and Bhandari, A., 2011. Recent updates on codeine. Pharmaceutical methods, 2(1),
pp.3-8.
Kahan, M.M., 2011. The opioid crisis in North America. Canadian Family Physician, 57(5), pp.5
Therapeutic Goods Administration (TGA). 2020. Codeine Information Hub. [online] Available at:
<https://www.tga.gov.au/node/753795> [Accessed 16 May 2020].36-536.
International Narcotics Control Board. Narcotic drugs estimated world requirements for 2012. Vienna: INCB,
2012.
Pharmaceutical Society of Ireland. Non-Prescription Medicinal Products Containing Codeine: Guidance for
Pharmacists on Safe Supply to Patients. Guidance for Retail Pharmacy Businesses. Pharmaceutical Society of
Ireland; 2017 p. 2-6.
Carrington Reid, M., Eccleston, C., Pillemar, K., 2015. Management of chronic pain in older adults.
Cairns R et al. 2019. Codeine use and harms in Australia: evaluating the efforts of re-scheduling. Available at:
https://onlinelibrary.wiley.com/doi/10.1111/add.14798
Beyene K, et al. 2014. Prescription medication sharing: A systematic review of the literature. Available at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025682/
Kennedy-Hendricks A et al. 2016. Medication Sharing, Storage, and Disposal Practices for Opioid Medications
Among US Adults. Available at: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2527388
Weston, C., 2019. Revealed: How Much We Spend Visiting The Doctor Each Year. [online]independent. Available
at: <https://www.independent.ie/business/personal-finance/revealed-how-much-we-spend-visiting-the-doctoreach-year-36699145.html>.
Shying O (2018) Codeine user says price hike will turn pain sufferers to illegal drugs. Geelong Advertiser.
Kennedy C et al (2019) Rates of reported codeine-related poisonings and codeine prescribing following new
national guidance in Ireland. Pharmacoepidemiology and Drug Safety, 28, (1), pp. 106-111.

